82419-35-0

Basic information

• Product Name: Oxygen-fluorine acid
• Synonyms: AURORA 21894;AKOS BBS-00001807;9,10-DIFLUORO-2,3-DIHYDRO-3-METHYL-7-OXO-7H-PYRIDO[1,2,3-DE]-1,4-BENZ-OXAZINE-6-CARBOXYLIC ACID;9,10-difluoro-2,3-dihydro-3-methyl-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxyllic acid;9,10-DIFLUORO-3-METHYL-7-OXO-2,3-DIHYDRO-7H-[1,4]OXAZINO[2,3,4-IJ]QUINOLINE-6-CARBOXYLIC ACID;OXYGEN-FLUORINE ACID;OTAVA-BB BB0111050010;9,10-Difluoro-3-Methyl-7-Oxo-2,3-Dihydro 7-H-Pyrido-1,2,3-DE]-1,4-Benzoxyazine-6-Carboxylic Acid
• CAS NO: 82419-35-0
• Molecular Formula: C₁₃H₉F₂NO₄
• Molecular Weight: 281.21
• EINECS: 1806241-263-5
• Product Categories: OFLOXACIN INTERMIDATE;Various Intermediates;Intermediates;Intermediates & Fine Chemicals;Pharmaceuticals;Benzoxazines;Building Blocks;Heterocyclic Building Blocks
• Mol File: 82419-35-0.mol
• Article Data: 10

Chemical Properties

• Melting Point: 320-322 °C(lit.)
• Boiling Point: 459.2 °C at 760 mmHg
• Flash Point: 231.5 °C
• Appearance: grey-yellow powder
• Density: 1.61 g/cm³
• Vapor Pressure: 3.14E-09mmHg at 25°C
• Storage Temp.: -20?C Freezer
• Solubility: DMSO (Slightly, Heated)
• PKA: 4.87±0.40(Predicted)
• BRN: 4202751
• CAS DataBase Reference: Oxygen-fluorine acid(CAS DataBase Reference)
• NIST Chemistry Reference: Oxygen-fluorine acid(82419-35-0)
• EPA Substance Registry System: Oxygen-fluorine acid(82419-35-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 82419-35-0(Hazardous Substances Data)

Usage

Chemical Properties

Grey-Yellow Powder

Uses

Different sources of media describe the Uses of 82419-35-0 differently. You can refer to the following data:
1. Ofloxacin intermediate
2. 9,10-Difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid (Ofloxacin EP Impurity A) is an Ofloxacin intermediate.

General Description

(S)-(-)-9,10-Difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid may be used in the preparation of the following:kynurenine aminotransferase II (KAT II) inhibitor, [(S)-(-)-9-(4-aminopiperazine-1-yl)-8-fluoro-3-methyl-6-oxo-2,3,5,6-tetrahydro-4H-1-oxa-3a-aza-phenalene-5-carboxylic acid]fused-ring derivativesN-desmethyllevofloxacin

InChI:InChI=1/C13H9F2NO4/c1-5-4-20-12-9(15)8(14)2-6-10(12)16(5)3-7(11(6)17)13(18)19/h2-3,5H,4H2,1H3,(H,18,19)/p-1/t5-/m1/s1

Upstream product

• 178233-30-2 ethyl 2-(2-nitro-3,4,5-trifluoro) benzoyl-3-(1-t-butyldimethylsilyloxyprop-2-ylamino) acrylate 
• 429-41-4 tetrabutyl ammonium fluoride 
• 113933-52-1 ethyl 2-(2,3,4,5-tetrafluorobenzoyl)-3-(1-hydroxyprop-2-ylamino)acrylate 
• 94695-50-8 ethyl 3-(2,3,4,5-tetrafkuorophenyl)-3-oxopropanoate 
• 82419-33-8 (-)-7,8-difluoro-2,3-dihydro-3-methyl-4H-1,4-benzoxazine 
• 82419-26-9 2,3-difluoro-6-nitrophenol 
• 82419-32-7 3,4-difluoro-2-(2-oxopropyloxy)nitrobenzene 
• 771-69-7 2,3,4-trifluoronitrobenzene 
• 124409-86-5 diethyl [3,4-difluoro-2-(2-hydroxypropyloxy)anilinyl]methylenemalonate 
• 144298-04-4 (3,4-difluorophenyl)-carbamic acid-tert-butyl ester 
• 85741-74-8 diethyl 2-(((3,4-difluoro-2-hydroxyphenyl)amino)methylene)malonate 
• 115551-33-2 2-hydroxy 3,4-difluoro aniline 
• 86760-99-8 diethyl [(-)-7,8-difluoro-3-methyl-2,3-dihydro-4H-[1,4]benzoxazin-4-yl]methylenemalonate 
• 107359-16-0 ethyl 6,7,8-trifluoro-1,4-dihydro-1-(1-hydroxyprop-2-yl)-4-oxoquinoline-3-carboxylate 

Downstream Products

• 131683-67-5 9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-3-methyl-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid 
• 82419-36-1 ofloxacin 
• 1351976-07-2 C₂₉H₂₃F₆N₃O₁₀ 
• 1093659-16-5 9-fluoro-2,3-dihydro-3-methyl-10-[[(4-methoxyphenyl)methyl]amino]-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid 
• 444335-14-2 9-(4-{4-[5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenyl}-piperazin-1-yl)-8-fluoro-3-methyl-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid 
• 86794-25-4 9-(4-Benzyl-piperazin-1-yl)-8-fluoro-3-methyl-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid 
• 86794-24-3 8-Fluoro-3-methyl-6-oxo-9-(4-phenyl-piperazin-1-yl)-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid 
• 124255-93-2 8-Fluoro-3-methyl-6-oxo-9-(4-propyl-piperazin-1-yl)-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid 
• 82419-59-8 8-Fluoro-3-methyl-9-(4-methyl-[1,4]diazepan-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid 
• 124338-73-4 9-(4-Ethyl-piperazin-1-yl)-8-fluoro-3-methyl-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid 
• 82419-52-1 N-Demethylofloxacin 

Relevant articles and documents

Ofloxacin preparation method (by machine translation)

The invention provides a preparation method of ofloxacin. The preparation method comprises the following steps of: reacting (N,N)-dimethylamino ethyl acrylate with aminopropanols in methylbenzene; directly adding lewis base serving as a catalyst and trimethylchlorosilane to protect hydroxyl and amido; after reaction is completely finished, dropwise adding (2,3,4,5)-tetrafluorobenzoyl chloride; preserving heat; performing acid washing; removing protecting groups; concentrating an organic layer to obtain an oil layer; adding a proper amount of dimethyl formamide (DMF); diluting and dropwise adding backflow DMF having anhydrous potassium fluoride; recovering DMF and adding water to centrifuge; adding acid water into a solid to hydrolyze to obtain difluorocarboxylic acid; and completely reacting difluorocarboxylic acid and N-methyl piperazine in dimethylsulfoxide (DMSO) by using triethylamine as an acid-binding agent at 90-100 DEG C to obtain ofloxacin. According to the process, hydroxyl and amido are protected by using trimethylchlorosilane, so that the utilization degree of (2,3,4,5)-tetrafluorobenzoyl chloride is effectively increased, and the generation of impurities is reduced to ensure that the reaction yield of intermediate difluorocarboxylic acid is increased by 10 percent.

Novel oxazolidinone-quinolone hybrid antimicrobials

Antimicrobial compounds incorporating oxazolidinone and quinolone pharmacophore substructures have been synthesized and evaluated. Representative analogues 2, 5, and 6 display an improved potency versus linezolid against gram-positive and fastidious gram-negative pathogens. The compounds are also active against linezolid- and ciprofloxacin-resistant Staphylococcus aureus and Enterococcus faecium strains. The MOA for these new antimicrobials is consistent with a combination of protein synthesis and gyrase A/topoisomerase IV inhibition, with a structure-dependent degree of the contribution from each inhibitory mechanism.

An efficient synthesis of ofloxacin and levofloxacin from 3,4- difluoroaniline

The functionalization at either C-2 or C-3 of N-(tert-butoxycarbonyl)- 3,4-difluoroaniline based on its ortho-deprotonation under different experimental conditions is described. This kind of products can be readily applied to the synthesis of ofloxacin, levofloxacin and related compounds.